![](/img/cover-not-exists.png)
Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial
Maurie Markman, P.Y. Liu, James Moon, Bradley J. Monk, Larry Copeland, Sharon Wilczynski, David AlbertsVolume:
114
Year:
2009
Language:
english
Pages:
4
DOI:
10.1016/j.ygyno.2009.04.012
File:
PDF, 307 KB
english, 2009